Monopar Therapeutics (MNPR) Current Assets (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Current Assets data on file, last reported at $140.5 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets rose 132.97% year-over-year to $140.5 million; the trailing twelve-month figure through Dec 2025 stood at $140.5 million (up 132.97% YoY), and the FY2025 full-year result was $140.5 million, up 132.97% from the prior year.
• Current Assets eased to $140.5 million in Q4 2025, from $144.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $144.1 million in Q3 2025 to a low of $6.1 million in Q3 2024.
• A 5-year average of $33.5 million and a median of $17.3 million in 2022 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 44.31% in 2023 and jumped 2273.95% in 2025, its largest moves.
• Tracing MNPR's Current Assets over 5 years: stood at $20.5 million in 2021, then plunged by 35.84% to $13.2 million in 2022, then tumbled by 44.31% to $7.3 million in 2023, then surged by 722.24% to $60.3 million in 2024, then soared by 132.97% to $140.5 million in 2025.
• Business Quant data shows MNPR's Current Assets at $140.5 million in Q4 2025, $144.1 million in Q3 2025, and $53.7 million in Q2 2025.